Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. It is also developing BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; ALKS 3831 to treat schizophrenia; ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy; and ALKS 5461 for the treatment of depressive disorders. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. It also has a research collaboration with Clovis Oncology, Inc. to evaluate ALKS 4230 in combination with Clovis rucaparib, a PARP inhibitor and lucitanib, an investigational tyrosine kinase inhibitor. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone353-1772-8000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.09 billion
Profitability
Miscellaneous
Employees2,300
Next Earnings Date4/25/2019 (Estimated)
OptionableOptionable
Alkermes (NASDAQ:ALKS) Frequently Asked Questions
What is Alkermes' stock symbol?
Alkermes trades on the NASDAQ under the ticker symbol "ALKS."
How were Alkermes' earnings last quarter?
Alkermes Plc (NASDAQ:ALKS) issued its quarterly earnings results on Thursday, February, 14th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.05) by $0.39. The firm had revenue of $316 million for the quarter, compared to analyst estimates of $255.71 million. Alkermes had a negative return on equity of 0.49% and a negative net margin of 12.73%. The company's revenue was up 14.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.31 earnings per share. View Alkermes' Earnings History.
When is Alkermes' next earnings date?
What guidance has Alkermes issued on next quarter's earnings?
Alkermes updated its FY19 earnings guidance on Thursday, February, 14th. The company provided earnings per share (EPS) guidance of $0.25-0.43 for the period, compared to the Thomson Reuters consensus estimate of $0.64. The company issued revenue guidance of $1.14-1.19 billion, compared to the consensus revenue estimate of $1.10 billion.Alkermes also updated its FY 2019 guidance to $0.25-0.43 EPS.
What price target have analysts set for ALKS?
13 analysts have issued twelve-month target prices for Alkermes' stock. Their forecasts range from $26.00 to $63.00. On average, they anticipate Alkermes' share price to reach $44.8333 in the next twelve months. This suggests a possible upside of 32.0% from the stock's current price. View Analyst Price Targets for Alkermes.
What is the consensus analysts' recommendation for Alkermes?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 3 sell ratings, 5 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Alkermes.
What are Wall Street analysts saying about Alkermes stock?
Here are some recent quotes from research analysts about Alkermes stock:
- 1. According to Zacks Investment Research, "Alkermes’ earnings and sales beat estimates in the fourth quarter of 2018. With the increasing traction of Aristada in the market, the company continues to emerge as a leader in the treatment of schizophrenia. The company released positive results of the ALKS 3831 ENLIGHTEN-2 pivotal study. This year will be an important one for the company’s late-stage pipeline highlighted by the planned submission of the NDA for ALKS 3831 and the regulatory review of the recently submitted NDA for diroximel fumarate for multiple sclerosis, with action expected in the fourth quarter. The company also expects to have release data from ALKS 4230's anti-tumor response study in 2019. However, Alkermes is highly dependent on manufacturing and/or royalty revenues. Shares have outperformed the industry in the last three months." (3/22/2019)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate the Neutral rating for ALKS stock and are reducing our PT by $5 to $41. We believe the FDA advisory panel view of the ALKS-5461 NDA is a major setback not only for the drug but also to the ability of ALKS to convince investors that the company can develop proprietary therapies of meaningful commercial potential." (11/5/2018)
Has Alkermes been receiving favorable news coverage?
News coverage about ALKS stock has trended somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Alkermes earned a news impact score of 0.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future.
Who are some of Alkermes' key competitors?
Some companies that are related to Alkermes include Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Mylan (MYL), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Ionis Pharmaceuticals (IONS), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ) and SAGE Therapeutics (SAGE).
What other stocks do shareholders of Alkermes own?
Who are Alkermes' key executives?
Alkermes' management team includes the folowing people:
- Mr. Richard F. Pops, Chairman & CEO (Age 57)
- Dr. Floyd E. Bloom, Co-Founder & Director (Age 82)
- Mr. James M. Frates, Sr. VP, CFO & Treasurer (Age 52)
- Mr. James A. Robinson Jr., Pres & COO (Age 49)
- Mr. Iain Michael Brown, Sr. VP of Fin. & Chief Accounting Officer (Age 50)
Who are Alkermes' major shareholders?
Alkermes' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (10.24%), BlackRock Inc. (6.48%), First Trust Advisors LP (1.45%), Geode Capital Management LLC (1.00%), Geode Capital Management LLC (0.99%) and Thornburg Investment Management Inc. (0.79%). Company insiders that own Alkermes stock include David W Anstice, Elliot Ehrich, Floyd E Bloom, Iain Michael Brown, James M Frates, Kathryn L Biberstein, Laurie Keating, Mark Stejbach, Michael J Landine, Nancy Wysenski, Paul J Mitchell, Richard F Pops and Shane Cooke. View Institutional Ownership Trends for Alkermes.
Which major investors are selling Alkermes stock?
ALKS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Bank of New York Mellon Corp, Meditor Group Ltd, Rhenman & Partners Asset Management AB, Bank of America Corp DE, Los Angeles Capital Management & Equity Research Inc., Royal London Asset Management Ltd. and KBC Group NV. Company insiders that have sold Alkermes company stock in the last year include David W Anstice, Floyd E Bloom, James M Frates, Michael J Landine, Paul J Mitchell and Richard F Pops. View Insider Buying and Selling for Alkermes.
Which major investors are buying Alkermes stock?
ALKS stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Two Sigma Investments LP, Canada Pension Plan Investment Board, First Manhattan Co., Korea Investment CORP, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP and Two Sigma Advisers LP. View Insider Buying and Selling for Alkermes.
How do I buy shares of Alkermes?
Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alkermes' stock price today?
One share of ALKS stock can currently be purchased for approximately $33.96.
How big of a company is Alkermes?
Alkermes has a market capitalization of $5.30 billion and generates $1.09 billion in revenue each year. The company earns $-139,310,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. Alkermes employs 2,300 workers across the globe.
What is Alkermes' official website?
How can I contact Alkermes?
Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]
MarketBeat Community Rating for Alkermes (NASDAQ ALKS)
MarketBeat's community ratings are surveys of what our community members think about Alkermes and other stocks. Vote "Outperform" if you believe ALKS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALKS will underperform the S&P 500 over the long term. You may vote once every thirty days.
